<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Zhenyu</forename><surname>Hou</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">The Second Department of Surgery</orgName>
								<orgName type="institution" key="instit1">Nankai Hospital</orgName>
								<orgName type="institution" key="instit2">Tianjin Medical University</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Professor</roleName><forename type="first">Yunfeng</forename><surname>Cui</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">The Second Department of Surgery</orgName>
								<orgName type="institution" key="instit1">Nankai Hospital</orgName>
								<orgName type="institution" key="instit2">Tianjin Medical University</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Huizhi</forename><surname>Xing</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of General Surgery</orgName>
								<orgName type="institution" key="instit1">The Affiliated Hospital</orgName>
								<orgName type="institution" key="instit2">Logistics University of CATF</orgName>
								<address>
									<postCode>300162</postCode>
									<settlement>Tianjin</settlement>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xiaoyan</forename><surname>Mu</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of General Surgery</orgName>
								<orgName type="institution" key="instit1">The Affiliated Hospital</orgName>
								<orgName type="institution" key="instit2">Logistics University of CATF</orgName>
								<address>
									<postCode>300162</postCode>
									<settlement>Tianjin</settlement>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">The</forename><surname>Second</surname></persName>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of Surgery</orgName>
								<orgName type="institution" key="instit1">Nankai Hospital</orgName>
								<orgName type="institution" key="instit2">Tianjin Medical University</orgName>
								<address>
									<addrLine>6 Changjiang Road</addrLine>
									<postCode>300162</postCode>
									<settlement>Tianjin</settlement>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">192A7F485D970EDBFD9DD2C8FC9B0018</idno>
					<idno type="DOI">10.3892/ol.2017.7500</idno>
					<note type="submission">Received June 19, 2016; Accepted August 8, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>poly(ADP-ribose) polymerase</term>
					<term>pancreatic cancer</term>
					<term>p53</term>
					<term>ataxia telangiectasia mutated</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The present study investigated whether poly(ADP-ribose) polymerase (PARP) has an effect on p53-regulated pancreatic cancer.</s><s>The results of the present study demonstrated that the expression of PARP affects proliferation and apoptosis of pancreatic cancer cells.</s><s>Olaparib was used to suppress the expression level of PARP-1 in PanC-1 cells.</s><s>Decreased expression of PARP-1 suppressed cell proliferation and induced apoptosis of PanC-1 cells when compared with controls.</s><s>Furthermore, decreased expression of PARP-1 resulted in decreased levels of pro-caspase-3 expression, increased caspase-3 activity, suppressed B-cell lymphoma 2 (Bcl-2) protein expression and increased p53 protein expression in PanC-1 cells.</s><s>Subsequently, ataxia telangiectasia mutated (ATM) activity was inhibited alongside down-expression of PARP-1 resulting in significantly decreased cellular viability of PanC-1 cells, increased p53 protein expression, decreased expression of pro-caspase-3, increased caspase-3 activity and suppressed Bcl-2 protein expression, when compared with PARP-1 suppression alone.</s><s>Overall, the in vitro data confirmed that down-expression of PARP-1 suppressed cell proliferation and induced apoptosis of pancreatic cancer via ATM-deficient p53 signaling pathway.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Pancreatic cancer is a result of malignant tumor growth in the digestive system <ref type="bibr" target="#b0">(1)</ref>.</s><s>Relative to other types of cancer, pancreatic cancer involves late identification of lesions, a high degree of malignance, fast progression and poorer prognosis <ref type="bibr" target="#b0">(1)</ref>.</s><s>Previous research has demonstrated that pancreatic cancer primarily presents in the head of pancreas <ref type="bibr" target="#b1">(2)</ref>.</s><s>The morbidity of patients with pancreatic ductal adenocarcinoma is the highest amongst pancreatic cancer and accounts for 95% of pancreatic cancer-associated mortality <ref type="bibr" target="#b1">(2)</ref>.</s><s>The 5-year survival rate of pancreatic cancer is &lt;5% (3), and patients with pancreatic cancer are expected to survive for ~4-6 months after diagnosis prior to succumbing to the disease <ref type="bibr" target="#b3">(4)</ref>.</s><s>Patients who undergo surgery are expected to live for ~13-20 months before succumbing to pancreatic cancer <ref type="bibr" target="#b1">(2)</ref>.</s><s>The annual morbidity rate of patients with pancreatic cancer is ~9/10,000, with the morbidity rate in China being ~5/10,000 <ref type="bibr" target="#b2">(3)</ref>.</s><s>Annually, ~40,000 people succumb to pancreatic cancer <ref type="bibr" target="#b2">(3)</ref>.</s><s>Previous research has revealed that the morbidity rate of pancreatic cancer in China is increasing <ref type="bibr" target="#b3">(4)</ref>.</s></p><p><s>Inhibition of apoptosis serves a role in the progression of pancreatic cancer.</s><s>Proteins in the B-cell lymphoma 2 (Bcl-2) family serve an important role in the regulation of apoptosis <ref type="bibr" target="#b4">(5)</ref>.</s><s>The Bcl-2 family includes the apoptotic inhibitors Bcl-2, B-cell lymphoma extra-large (Bcl-xL), Bcl-2-like protein 2 (Bcl-w), Bcl-2-related protein A1 (Bfl-1), brefeldin A-resistant Arf-guanine nucleotide exchange factor 1 (Brag-1) and induced myeloid leukemia cell differentiation protein (Mcl-1), and the apoptotic regulators Bcl-2-associated X protein (Bax), Bcl-2 homologous antagonist/killer (Bak), B-cell lymphoma extra-small (Bcl-xS), Bcl-2-associated death promoter (Bad), BH3 interacting-domain death agonist (Bid), Bcl-2-interacting killer (Bik) and activator of apoptosis hara-kiri (Hrk) <ref type="bibr" target="#b5">(6)</ref>.</s><s>The ratio of apoptotic inhibitors to apoptotic inducers determines the response of cells to apoptosis-triggering signals.</s><s>To some extent, induction and inhibition of apoptosis may be regulated by controlling the expression of various Bcl-2 family members <ref type="bibr" target="#b6">(7)</ref>.</s><s>p53 is the primary regulator of the Bcl-2 family.</s><s>The biological behavior of pancreatic cancer tumor cells is thus affected by the regulatory properties exhibited by p53 over the various inhibitors and inducers of apoptosis within the Bcl-2 family <ref type="bibr" target="#b7">(8)</ref>.</s></p><p><s>Poly(ADP-ribose) polymerase (PARP) requires an oxidized nicotinamide-adenine dinucleotide substrate, utilizing adenosine triphosphate in order to form a poly(ADP-ribose) chain (PAR chain) at the site of single strand breaks in DNA <ref type="bibr" target="#b8">(9)</ref>.</s><s>The formation of a PAR chain signals other DNA damage repair proteins to the site of the break.</s><s>PARP has exhibited involvement in a number of metabolic processes in cells including genome stabilization, cell cycle progression, gene transcription, chromosome function and cell death.</s><s>The PARP family has a number of distinct members including; PARP-1, PARP-2, PARP-3, Vault-PARP and tankyrases.</s><s>PARP-1 was the first member of the PARP family to be identified, with a molecular mass of 116Kd <ref type="bibr" target="#b8">(9)</ref>.</s><s>It comprises three regions: A DNA-binding domain, an automodification domain and a catalytic domain <ref type="bibr" target="#b9">(10)</ref>.</s><s>The primary structure of PARP-1 is highly conserved in eukaryotes; distinct catalytic regions exhibit a high degree of homology <ref type="bibr" target="#b9">(10)</ref>.</s><s>Increased expression levels of PARP-1 have been identified in multiple types of tumor including breast, prostate and pancreatic cancer, indicating that PARP-1 participates in tumorigenesis and tumor progression <ref type="bibr" target="#b10">(11)</ref>.</s><s>In order to develop effective novel therapeutic approaches to treat pancreatic cancer, the underlying molecular mechanisms of the involvement of PARP-1 in tumor progression require investigation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head><p><s>Cell lines and cell culture.</s><s>Human pancreatic cancer cells (PanC-1) were provided by the Institute of Biochemistry and Cell Biology (Chinese Academy of Science Shanghai, China).</s><s>PanC-1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific, Inc.), penicillin (50 U/ml) and streptomycin (50 µg/ml) at 37˚C in a humidified atmosphere containing 5% CO 2 .</s></p><p><s>Cell proliferation assay.</s><s>PanC-1 cells (1x10 3 in a 96-well plate) were cultured in the presence of dimethylsulfoxide (DMSO; Amresco, LLC, Solon, OH, USA; untreated) or olaparib (1, 5 and 25 µM; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 1, 2, 3 and 4 days at 37˚C.</s><s>A second set of experiments was performed, with PanC-1 cells (1x10 3 in a 96-well plate) cultured in the presence of DMSO (untreated), olaparib (5 µM) or olaparib (5 µM) + KU55933 (5 µM) for 4 days at 37˚C.</s><s>Subsequently, 20 µl/well MTT solution (5 mg/ml; Amresco, LLC) was added to each well prior to further incubation at 37˚C for 4 h.</s><s>Subsequently, DMSO solution was added to each well for solubilization of the formazan product at 37˚C for 30 min with gentle mixing.</s><s>Absorbance was determined at 560 nm using an M200 plate reader (Tecan Group, Ltd., Mannedorf, Switzerland).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of apoptosis using flow cytometry (FCM).</head><p><s>PanC-1 cells (1x10 6 in a 6-well plate) were cultured in the presence of DMSO (untreated) or olaparib (1, 5 and 25 µM) for 4 days at 37˚C.</s><s>A second set of experiments was performed, with PanC-1 cells (1x10 6 in a 6-well plate) cultured in the presence of DMSO (untreated), olaparib (5 µM) or olaparib (5 µM) + KU55933 (5 µM) for 4 days at 37˚C.</s><s>Subsequently PanC-1 cells were washed twice with PBS and resuspended in 500 µl binding buffer (BD Biosciences, Franklin Lakes, NJ, USA) and 5 µl annexin V-fluorescein isothiocyanate (FITC) (BD Biosciences) and subsequently in 5 µl propidium iodide (PI) (BD Biosciences) in the dark.</s><s>The rate of apoptosis was analyzed using FCM (BD Biosciences).</s></p><p><s>Caspase-3 activity determination using a caspase-3 activity kit.</s><s>The caspase-3 activity kit it was obtained from Beyotime Institute of Biotechnology (Haimen, China; C1115).</s><s>PanC-1 cells (1x10 6 in a 6-well plate) were cultured in the presence of DMSO (untreated) or olaparib (1, 5 and 25 µM) for 4 days at 37˚C.</s><s>A second set of experiments was performed, with PanC-1 cells (1x10 6 in a 6-well plate) cultured in the presence of DMSO (untreated), olaparib (5 µM) or olaparib (5 µM) + KU55933 (5 µM) for 4 days at 37˚C.</s><s>Subsequently PanC-1 cells were washed twice with PBS and incubated with N-acetyl-Asp-Glu-Val-Asp-p-nitroanilide (C1115; Beyotime Institute of Biotechnology) at 37˚C for 30 min.</s><s>Absorbance was determined at 405 nm using an M200 plate reader.</s></p><p><s>Western blot analysis.</s><s>PanC-1 cells (1x10 6 in 6-well plate) were cultured in the presence of DMSO (untreated) or olaparib (1, 5 and 25 µM) for 1, 2, 3 and 4 days at 37˚C.</s><s>A second set of experiments was performed, with PanC-1 cells (1x10 6 in a 6-well plate) cultured in the presence of DMSO (untreated), olaparib (5 µM) or olaparib (5 µM) + KU55933 (5 µM) for 4 days at 37˚C.</s><s>Subsequently, PanC-1 cells were lysed in radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology) with phenylmethanesulfonyl fluoride protease and phosphatase inhibitor (Beyotime Institute of Biotechnology).</s><s>Total cell protein was extracted and subsequently quantified using a BCA protein quantitative assay kit (Beyotime Institute of Biotechnology).</s><s>An equivalent amount of protein (50 µg) was resolved using SDS-PAGE (8-12% gel) and transferred on to a nitrocellulose membrane (Merck KGaA).</s><s>Membranes were blocked with skimmed milk (5%) in TBST (with 0.1% Tween-20) for 1 h at 37˚C and then incubated with anti-pro-caspase-3 (sc-98785; 1:500; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-Bcl-2 (sc-783; 1:300; Santa Cruz Biotechnology, Inc.), anti-p53 (sc-6243; 1:500; Santa Cruz Biotechnology, Inc.) and anti-GAPDH (sc-25778, 1:500; Santa Cruz Biotechnology, Inc.) at 4˚C overnight.</s><s>Horseradish peroxidase-labeled goat anti-rabbit secondary antibodies (sc-2004; 1:5,000, Sangon Biotech Co., Ltd., Shanghai, China) were added for 1 h at 37˚C and detected using enhanced chemiluminescence reagent (Bio-Rad Laboratories, Inc., Hercules, CA, USA).</s><s>The protein expression was measured using ImageJ 1.37 software (National Institutes of Health, Bethesda, MD, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis.</head><p><s>All data are presented as the mean ± standard deviation.</s><s>Analysis of variance was used for multiple comparisons and Student's t-test was used to compare between pairs.</s><s>P&lt;0.05 was considered to indicate a statistically significant difference.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Down-expression of PARP-1 suppresses the proliferation of</head><p><s>PanC-1 cells.</s><s>To investigate whether the down-expression of PARP-1 has an effect on human pancreatic cancer, an MTT assay was used to measure the proliferation of PanC-1 cells following treatment with olaparib.</s><s>It was demonstrated that olaparib, a PARP-1 inhibitor, significantly suppressed the proliferation of PanC-1 cells in a time-and dose-dependent manner when compared with the DMSO control group (Fig. <ref type="figure" target="#fig_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Down-expression of PARP-1 induces apoptosis of PanC-1 cells.</head><p><s>To investigate whether the down-expression of PARP-1 induces apoptosis of PanC-1 cells following olaparib treatment, FCM was performed.</s><s>Cells treated with olaparib (5 and 10 µM) exhibited a significant increase in the rate of apoptosis in a dose-dependent manner when compared with the DMSO control group (Fig. <ref type="figure" target="#fig_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Down-expression of PARP-1 decreases pro-caspase-3 expression levels and increases caspase-3 activity in</head><p><s>PanC-1 cells.</s><s>Pro-caspase-3 was analyzed using western blotting and a caspase-3 activity kit.</s><s>Pro-caspase-3 expression levels were significantly suppressed following down-expression of PARP-1, compared with the DMSO control group.</s><s>However, caspase-3 activity was significantly increased following down-expression of PARP-1 when compared with the DMSO control group (Fig. <ref type="figure" target="#fig_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Down-expression of PARP-1 suppresses Bcl-2 protein expression of PanC-1 cells.</head><p><s>To quantify cell death, Bcl-2 protein expression levels in PanC-1 cells were measured using western blot analysis.</s><s>The results demonstrated that olaparib significantly inhibited the expression of Bcl-2 protein in a dose-dependent manner when compared with the DMSO control group (Fig. <ref type="figure" target="#fig_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Down-expression of PARP-1 induces p53 protein expression in</head><p><s>PanC-1 cells.</s><s>To further investigate the effect of down-expression of PARP-1 on cell death, the expression levels of p53 protein in PanC-1 cells was measured using western blot analysis.</s><s>It was identified that increasing concentrations of olaparib resulted in increased expression levels of p53 protein (Fig. <ref type="figure" target="#fig_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inhibition of ataxia telangiectasia mutated (ATM) activity alongside down-expression of PARP-1 further suppresses the proliferation of PanC-1 cells.</head><p><s>Functional ATM caused anchorage-independent proliferation in pancreatic cancer.</s><s>KU55933 (5 µM) was used to inhibit ATM activity.</s><s>As presented in Fig. <ref type="figure" target="#fig_3">4</ref>, following treatment with KU55933 (5 µM) and olaparib (5 µM) cell proliferation was decreased when compared with the olaparib (5 µM)-treated group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inhibition of ATM activity alongside down-expression of PARP-1 further increases the rate of apoptosis of PanC-1 cells.</head><p><s>To investigate ATM activity in PanC-1 cells following olaparib treatment, the rate of apoptosis of PanC-1 cells was analyzed using FCM.</s><s>It was identified that the down-expression of PARP-1 alongside inhibition of ATM activity (inhibited using KU55933; 5 µM) significantly increased the rate of apoptosis of PanC-1 cells when compared with the olaparib (5 µM)-treated group (Fig. <ref type="figure" target="#fig_4">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inhibition of ATM activity in conjunction with down-expression of PARP-1 decreases pro-caspase-3 expression levels and increases caspase-3 activity in</head><p><s>PanC-1 cells.</s><s>Following treatment with KU55933 (5 µM) and olaparib (5 µM), pro-caspase-3 expression was significantly decreased and caspase-3 activity was significantly increased when compared with the olaparib (5 µM)-treated group (Fig. <ref type="figure" target="#fig_5">6</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inhibition of ATM activity alongside down-expression of PARP-1 suppresses Bcl-2 protein expression in PanC-1 cells.</head><p><s>The expression levels of Bcl-2 protein in PanC-1 cells were investigated using western blot analysis following inhibition of ATM activity using KU55933 (5 µM).</s><s>It was identified that down-expression of PARP-1 in conjunction with ATM inhibition significantly decreased Bcl-2 expression levels when compared with the olaparib (5 µM)-treated group (Fig. <ref type="figure" target="#fig_5">6</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inhibition of ATM activity in conjunction with down-expression of PARP-1 increases p53 protein expression levels of PanC-1 cells.</head><p><s>Expression levels of p53 were measured using western blot analysis.</s><s>Treatment with olaparib (5 µM) and KU55933 (5 µM) resulted in significantly increased p53 expression levels when compared with the olaparib (5 µM)-treated group (Fig. <ref type="figure" target="#fig_5">6</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Pancreatic cancer presents with a malignant tumor of the digestive tract and is a serious threat to human health.</s><s>Owing to a lack of typical clinical symptoms and the need for sensitive  diagnostic tests, by the time the majority of patients receive a diagnosis, their symptoms are too severe to be treated with surgical intervention.</s><s>The 5-year survival rate of pancreatic cancer is &lt;5% <ref type="bibr" target="#b1">(2)</ref>.</s><s>An increased understanding of the etiology of pancreatic cancer may result in the development of improved diagnostic tests.</s><s>It is hypothesized that pancreatic cancer is the result of multiple factors and genes.</s><s>Inactivation of p53 and p16, abnormal expression of the apoptosis inhibitor gene Bcl-2, inactivation of DNA damage repair genes, overexpression of growth factors and receptors, and an increase in telomerase activity are all hypothesized to serve a function in the development of pancreatic cancer <ref type="bibr" target="#b1">(2)</ref>.</s><s>PARP-1 is present in the majority of eukaryotic cells and serves an important role in DNA damage repair, genetic transcription, cell cycle progression, genome stabilization and cell death.</s><s>In the present study, it was identified that PARP-1 inhibition significantly suppressed cell proliferation, suppressed pro-caspase-3 protein expression and activated caspase-3 activity in PanC-1 cells.</s></p><p><s>Apoptosis is a type of programmed cell death regulated by genes in an active and orderly manner.</s><s>Effective apoptosis is achieved via p53 regulation <ref type="bibr" target="#b7">(8)</ref>.</s><s>Apoptosis regulation via p53 may be realized by upregulating Bax and downregulating Bcl-2 or Bcl-xL <ref type="bibr" target="#b11">(12)</ref>.</s><s>Through their interaction, the permeability of cell mitochondria is regulated, affecting the function of downstream apoptosis genes.</s><s>It has been demonstrated that Bcl-2 in pancreatic cancer tissue with increased expression of p53 is overexpressed, whereas pancreatic cancer tissue with decreased expression of p53 exhibits decreased expression levels of Bcl-2, indicating that Bcl-2 expression may be at least partially dependent on p53 expression levels <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b13">14)</ref>.</s><s>In the present study, it was identified that PARP-1 inhibition   significantly increased p53 expression levels in PanC-1 cells.</s><s>Deben et al <ref type="bibr" target="#b14">(15)</ref> reported that PARP inhibition induces apoptosis in non-small cell lung cancer cell lines via the p53 signaling pathway.</s></p><p><s>Bcl-2 family members exhibit the ability to form dimers or polymers by themselves or with other family members.</s><s>For example, a Bax-Bax dimer may induce apoptosis, whereas a Bcl-2-Bax dimer is more stable when compared with the former <ref type="bibr" target="#b15">(16)</ref>.</s><s>As a consequence of increased Bcl-2 expression, the proportion of Bcl-2-Bax dimers will be increased relative to Bax-Bax dimers, resulting in a decrease in pro-apoptotic Bax-Bax activity <ref type="bibr" target="#b16">(17)</ref>.</s><s>In the presence of Bcl-xS, formation of Bcl-xS-Bcl-2 dimer results in a decrease in Bcl-2-Bax dimer levels, which subsequently increases Bax-Bax levels, so as to induce apoptosis <ref type="bibr" target="#b17">(18)</ref>.</s><s>Therefore, the interaction between Bcl-2 family proteins regulates survival and apoptosis of cells.</s><s>The results of the present study demonstrated that PARP inhibition significantly inhibited the expression of Bcl-2 protein in PanC-1 cells.</s><s>Hao et al <ref type="bibr" target="#b18">(19)</ref> provided evidence that Tubeimoside-1 inhibits lung cancer cell proliferation and induces cell apoptosis through activation of PARP and the Bcl-2/Bax signaling pathway.</s></p><p><s>The mitochondrial apoptosis pathway is triggered by the activation and release of various apoptotic factors which regulate mitochondria by releasing apoptin which targets mitochondria <ref type="bibr" target="#b19">(20)</ref>.</s><s>Although regulation of apoptosis may include the Bcl-2 family, the final execution of apoptosis remains dependent on activation of the caspase cascade reaction <ref type="bibr" target="#b20">(21)</ref>.</s><s>The caspase family, particularly caspase-3, serves a key role in apoptosis <ref type="bibr" target="#b20">(21)</ref>.</s><s>Various apoptotic pathways lead to apoptosis by triggering the caspase cascade reaction.</s><s>Caspase-3 is the effector molecule in the apoptotic cascade signaling pathway and is the executive protein of apoptosis <ref type="bibr" target="#b21">(22)</ref>.</s><s>As a DNA damage repair molecule, PARP is degraded by caspase-3 and other cysteine proteinases during apoptosis, and its degradation is regarded as an early molecular sign of apoptosis <ref type="bibr" target="#b22">(23)</ref>.</s><s>In the present study, it was also identified that down-expression of PARP-1 (via olaparib) significantly decreased the cellular viability of PanC-1 cells, increased p53 protein expression, decreased expression of pro-caspase-3, increased caspase-3 activity and suppressed Bcl-2 protein expression following the inhibition of ATM activity.</s><s>Liu et al <ref type="bibr" target="#b23">(24)</ref> reported that PARP had an effect on sulfur mustard-induced cutaneous injuries in vitro and in vivo via the caspase-3 signaling pathway.</s></p><p><s>The results of the present study revealed that PARP-1 inhibition significantly suppressed cell proliferation, suppressed pro-caspase-3 protein expression and activated caspase-3 activity of PanC-1 cells through p53/Bcl-2 signaling.</s><s>Subsequently, inhibition of ATM activity alongside downregulation of PARP-1, further decreased cellular viability of PanC-1 cells, induced p53 protein expression, decreased expression of pro-caspase-3, increased caspase-3 activity, and suppressed Bcl-2 protein expression in PanC-1 cells.</s><s>It is proposed that down-expression of PARP-1 suppresses</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Decreased expression of PARP-1 suppresses the viability of PanC-1 cells.</s><s>** P&lt;0.01 vs. DMSO control group.</s><s>DMSO, dimethylsulfoxide.</s></p></div></figDesc><graphic coords="3,116.93,57.64,361.42,128.55" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Down-expression of PARP-1 induces apoptosis of PanC-1 cells.</s><s>** P&lt;0.01 vs. DMSO control group.</s><s>DMSO, dimethylsulfoxide.</s></p></div></figDesc><graphic coords="3,312.07,229.68,233.35,91.01" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Down-expression of PARP-1 decreases expression levels of pro-caspase-3, increases caspase-3 activity, decreases Bcl-2 expression levels and increases expression levels of p53 in PanC-1 cells.</s><s>(A) Down-expression of PARP-1 induces degradation of pro-caspase-3, Bcl-2 and increases p53 protein expression as determined using western blotting assays.</s><s>Quantification of (B) pro-caspase-3 protein expression, (C) caspase-3 activity, and (D) Bcl-2 and (E) p53 protein expression of PanC-1 cells.</s><s>** P&lt;0.01 vs. DMSO control group.</s><s>DMSO, dimethylsulfoxide; Bcl-2, B-cell lymphoma 2.</s></p></div></figDesc><graphic coords="4,68.74,57.39,457.80,300.98" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Inhibition of ataxia telangiectasia mutated activity in conjunction with down-expression of PARP-1 suppresses the proliferation of PanC-1 cells.</s><s>** P&lt;0.01 vs. DMSO control group; ## P&lt;0.01 vs. 5 µM olaparib-treated group.</s><s>DMSO, dimethylsulfoxide.</s></p></div></figDesc><graphic coords="4,50.66,430.64,231.76,86.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 .</head><label>5</label><figDesc><div><p><s>Figure 5. Inhibition of ataxia telangiectasia mutated activity alongside down-expression of PARP-1 increases the rate of apoptosis of PanC-1 cells.</s><s>** P&lt;0.01 vs. DMSO control group; ## P&lt;0.01 vs. 5 µM olaparib-treated group.</s><s>DMSO, dimethylsulfoxide.</s></p></div></figDesc><graphic coords="4,49.86,589.18,233.35,89.26" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 6 .</head><label>6</label><figDesc><div><p><s>Figure 6.</s><s>Inhibition of ataxia telangiectasia mutated (ATM) activity alongside down-expression of PARP-1 decreases expression levels of pro-caspase-3, increases caspase-3 activity, decreases Bcl-2 expression levels and increases p53 expression levels of PanC-1 cells.</s><s>(A) Western blot analysis results of levels of p53, Bcl-2, pro-caspase-3 and GAPDH in control cells, olaparib-treated cells and olaparib + KU55933-treated cells.</s><s>Quantification of (B) pro-caspase-3 protein expression, (C) caspase-3 activity, and (D) Bcl-2 and (E) p53 expression levels of PanC-1 cells.</s><s>** P&lt;0.01 vs. DMSO control group; ## P&lt;0.01 vs. 5 µM olaparib-treated group.</s><s>DMSO, dimethylsulfoxide; Bcl-2, B-cell lymphoma 2.</s></p></div></figDesc><graphic coords="5,71.07,57.39,453.13,311.33" type="bitmap" /></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>proliferation and induces apoptosis of pancreatic cancer cells via the ATM-deficient p53 signaling pathway.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hazama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Matsui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shindo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Iida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yoshimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yoshino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Takeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Oka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunother</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="36" to="42" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Pavlovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bodoky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Garin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Langmuir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Tidmarsh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1589" to="1596" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yang</forename><forename type="middle">Z</forename><surname>Aziz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Drugs</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="447" to="452" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Qing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">P</forename><surname>Ju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiat Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">6</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group</title>
		<author>
			<persName><forename type="first">U</forename><surname>Pelzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Schwaner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stieler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Seraphin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dörken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Riess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Oettle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="1676" to="1681" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R1</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S1</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ji</forename><forename type="middle">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Chen</forename><forename type="middle">H</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="7345" to="7355" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Lindqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Vaux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Autophagy</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1474" to="1475" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Z</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Mak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Mak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">R</forename><surname>Ruvolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mcqueen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Champlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Konopleva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Andreeff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="30487" to="30499" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">ADP-Ribose) polymerases: New players in the pathogenesis of exocrine pancreatic diseases</title>
		<author>
			<persName><forename type="first">N</forename><surname>Martinez-Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Fernandez-Zapico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Navarro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yelamos J:</forename><surname>Poly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="page" from="234" to="241" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ss-lapachone</title>
		<author>
			<persName><forename type="first">G</forename><surname>Chakrabarti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">R</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ilcheva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Padanad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Burma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Scaglioni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Metab</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">12</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Effects of combined treatment with ionizing radiation and the PARP inhibitor olaparib in BRCA mutant and wild type patient-derived pancreatic cancer xenografts</title>
		<author>
			<persName><forename type="first">I</forename><surname>Lohse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kumareswaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pitcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gallinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Bristow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Hedley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">e0167272</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Determination-of apoptosis and cell cycle modulators (p16, p21, p27, p53, BCL-2, Bax, BCL-xL and cyclin D1) in thyroid follicular carcinoma, follicular adenoma and adenomatous nodules via a tissue microarray method</title>
		<author>
			<persName><forename type="first">P</forename><surname>Temiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Akkaş</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Neşe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Uğur</forename><surname>Duman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Karakaş</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Erhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Turk J Med Sci</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="865" to="871" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Decrease of mitochondrial p53 during late apoptosis is linked to its dephosphorylation on serine 20</title>
		<author>
			<persName><forename type="first">C</forename><surname>Castrogiovanni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vandaudenard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Waterschoot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Backer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dumont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Biol Ther</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1296" to="1307" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Gemcitabine-mediated tumour regression and p53-dependent gene expression: Implications for colon and pancreatic cancer therapy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rabb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Madureira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Clements</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Gujar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wa Ism A N Dm</surname></persName>
		</author>
		<author>
			<persName><surname>Ia Com A Nt On Io Ca A Nd L E E Pw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">e791</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">APR-246 (PRIMA-1 (MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines</title>
		<author>
			<persName><forename type="first">C</forename><surname>Deben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lardon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wouters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Op De Beeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van Den Bossche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Van Der Steen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peeters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rolfo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Deschoolmeester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pauwels</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="313" to="322" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance</title>
		<author>
			<persName><forename type="first">C</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ye</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Pharmacother</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="133" to="139" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">BH4 domain of Bcl-2 as a novel target for cancer therapy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Wold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Discov Today</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="989" to="996" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The secret life of Bcl-2: Apoptosis-independent inhibition of DNA repair by Bcl-2 family members</title>
		<author>
			<persName><forename type="first">C</forename><surname>Laulier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Lopez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mutat Res</title>
		<imprint>
			<biblScope unit="volume">751</biblScope>
			<biblScope unit="page" from="247" to="257" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Tubeimoside-1 (TBMS1) inhibits lung cancer cell growth and induces cells apoptosis through activation of MAPK-JNK pathway</title>
		<author>
			<persName><forename type="first">W</forename><surname>Hao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wang</forename><forename type="middle">S</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Exp Pathol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="12075" to="12083" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The Bcl-2 family: Structures, interactions and targets for drug discovery</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kvansakul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Hinds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Apoptosis</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="136" to="150" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Prognostic value of Caspase-3 expression in cancers of digestive tract: A meta-analysis and systematic review</title>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wei</forename><forename type="middle">K</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Exp Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="10225" to="10234" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Lipopolysaccharide-enhanced early proliferation of insulin secreting NIT-1 cell is associated with nuclear factor-kappaB-mediated inhibition of caspase 3 cleavage</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">J</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">X</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Heemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin Med J (Engl)</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="3652" to="3656" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="5617" to="5626" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Effects of poly(ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo</title>
		<author>
			<persName><forename type="first">F</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Z</forename><surname>Mei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">R</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">B</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">X</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PeerJ</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">e1890</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
